Trade-Ideas LLC identified Celldex Therapeutics ( CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Celldex Therapeutics as such a stock due to the following factors:

  • CLDX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $27.3 million.
  • CLDX has traded 319,211 shares today.
  • CLDX is up 6.6% today.
  • CLDX was down 10.8% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CLDX with the Ticky from Trade-Ideas. See the FREE profile for CLDX NOW at Trade-Ideas

More details on CLDX:

Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. Currently there are 8 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Celldex Therapeutics has been 2.7 million shares per day over the past 30 days. Celldex has a market cap of $752.1 million and is part of the health care sector and drugs industry. The stock has a beta of 3.53 and a short float of 25.6% with 6.63 days to cover. Shares are down 56.6% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, feeble growth in its earnings per share, generally disappointing historical performance in the stock itself and weak operating cash flow.

Highlights from the ratings report include:
  • The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Biotechnology industry average. The net income has decreased by 13.9% when compared to the same quarter one year ago, dropping from -$28.08 million to -$31.98 million.
  • CELLDEX THERAPEUTICS INC' earnings per share from the most recent quarter came in slightly below the year earlier quarter. Earnings per share have declined over the last two years. We anticipate that this should continue in the coming year. During the past fiscal year, CELLDEX THERAPEUTICS INC reported poor results of -$1.32 versus -$1.03 in the prior year. For the next year, the market is expecting a contraction of 6.8% in earnings (-$1.41 versus -$1.32).
  • Looking at the price performance of CLDX's shares over the past 12 months, there is not much good news to report: the stock is down 72.32%, and it has underformed the S&P 500 Index. In addition, the company's earnings per share are lower today than the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • Net operating cash flow has declined marginally to -$27.79 million or 4.50% when compared to the same quarter last year. Despite a decrease in cash flow CELLDEX THERAPEUTICS INC is still fairing well by exceeding its industry average cash flow growth rate of -27.19%.
  • Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Biotechnology industry and the overall market, CELLDEX THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.